VPC-3033 is an androgen receptor antagonist. VPC-3033 has a strong androgen DHT replacement potency (IC50: 0.625-2.5 µM), can effectively inhibit androgen receptor transcriptional activity (IC50=0.3 µM), and has a strong androgen receptor degradation ability. In addition, VPC-3033 exhibits significant anti-androgen receptor activity against prostate cancer cells resistant to Enzalutamide (HY-70002)[1].
Molecular Weight:
298.33
CAS Number:
[110763-24-1]
Formula:
C21H14O2
Target:
Androgen Receptor
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
